Alx oncology to collaborate with lilly to evaluate alx148 plus cyramza® (ramucirumab), trastuzumab, and paclitaxel in patients with gastric or gastroesophageal junction cancer

Randomized phase 2/3 study is planned based on promising results from the aspen-01 phase 1b trial in gastric cancer patients randomized phase 2/3 study is planned based on promising results from the aspen-01 phase 1b trial in gastric cancer patients
ALXO Ratings Summary
ALXO Quant Ranking